QDENGA

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Romania, Spain, UK.

Active ingredients

The drug QDENGA contains a combination of these active pharmaceutical ingredients (APIs):

1	UNII 7FN6A2S3DZ - DENGUE VIRUS SEROTYPE 1
	Read more about
2	UNII 6QBH5B843J - DENGUE VIRUS SEROTYPE 2
	Read more about
3	UNII EE7A6LUD8F - DENGUE VIRUS SEROTYPE 3
	Read more about
4	UNII S28G939JPB - DENGUE VIRUS SEROTYPE 4
	Read more about

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QDENGA Powder and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BX04		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1893630, 1893641, 1893652, 1893663
ES	Centro de información online de medicamentos de la AEMPS	1221699005
FR	Base de données publique des médicaments	60919588, 69091949
IT	Agenzia del Farmaco	050458013, 050458025, 050458037, 050458049, 050458052, 050458064
LT	Valstybinė vaistų kontrolės tarnyba	1096066, 1096067, 1096068, 1096070, 1096071, 1096073
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69558001, W69558002, W69559001, W69559002, W69559003, W69559004